Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Her-2 Negative Metastatic Breast Cancer
-
Age: Between 18 years - 90 years
-
Gender: Male or Female
-
Other Inclusion Criteria:
- Histologically confirmed adenocarcinoma of the breast that is either TNBC or HER-2 negative.
- Received 0-2 lines of cytotoxic chemotherapy for metastatic breast cancer endocrine therapy and/or targeted therapy is allowed.
- Must have less than or equal to Grade 1 pre-existing peripheral neuropathy (as per CTCAE).
You may not be eligible for this study if the following are true:
-
- Hypersensitivity to pembrolizumab or any of its excipients.
- Has a known additional malignancy that progressed or required treatment within the last five years (exception: basal cell carcinoma of the skin or squamous cell carcinoma of the skin or in situ cervical cancer)
- Patients with known active central nervous system metastases and/or carcinomatous meningitis
- Taxane therapy within 3 months.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.